Evidence map›Paper›PMID 31107584›Full record

ArticleHead & neck2019

Patterns of care and survival impact of adjuvant chemoradiotherapy for oropharyngeal cancer with intermediate-risk features.

Alexander N Goel, Sophia Sangar, Laith Mukdad, Chase M Heaton, William R Ryan, Marilene B Wang, Jennifer L Long, Maie A St John

Open access · greenAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Head & neck, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Guideline
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Alexander N GoelDepartment of Otolaryngology-Head and Neck Surgery, Icahn School of Medicine at Mount Sinai, New York, New York.ORCID 0000-0002-9573-0318
Sophia SangarDepartment of Head and Neck Surgery, David Geffen School of Medicine at University of California, Los Angeles, California.
Laith MukdadDepartment of Head and Neck Surgery, David Geffen School of Medicine at University of California, Los Angeles, California.
Chase M HeatonDivision of Head and Neck Oncologic and Endocrine Surgery, Department of Otolaryngology-Head and Neck Surgery, University of California-San Francisco, San Francisco, California.
William R RyanDivision of Head and Neck Oncologic and Endocrine Surgery, Department of Otolaryngology-Head and Neck Surgery, University of California-San Francisco, San Francisco, California.
Marilene B WangDepartment of Head and Neck Surgery, David Geffen School of Medicine at University of California, Los Angeles, California.
Jennifer L LongDepartment of Head and Neck Surgery, David Geffen School of Medicine at University of California, Los Angeles, California.
Maie A St JohnDepartment of Head and Neck Surgery, David Geffen School of Medicine at University of California, Los Angeles, California.
University of California, Los Angeles · USUniversity of California, San Francisco · USIcahn School of Medicine at Mount Sinai · USWest Los Angeles College · US

Funding

Tissue engineering to regenerate functional vocal fold after scarring or tissue lossR01DC016959 · NIDCD · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LONG, JENNIFER L · 2018 to 2022
$3.7M
NIDCD NIH HHS R01 DC016959
6 · The paper itself

Abstract

backgroundSurvival outcomes for adjuvant chemoradiotherapy (aCRT) and adjuvant radiotherapy (aRT) were compared in patients with oropharyngeal squamous cell carcinoma (OPSCC) with intermediate-risk features.

methodsWe identified 2164 patients with OPSCC in the National Cancer Database without positive margins or extracapsular extension and with at least one intermediate-risk feature: pT3-T4 disease, ≥two positive lymph nodes, level IV/V nodal disease, and/or lymphovascular invasion. We assessed predictors of aCRT use and covariables impacting overall survival.

resultsaCRT was commonly used for both human papillomavirus (HPV)-positive (62.0%) and HPV-negative (64.3%) patients with OPSCC. Higher N stage, level IV/V neck disease, and younger age strongly predicted aCRT utilization. There was no significant survival benefit associated with aCRT vs aRT in HPV-positive (hazard ratio [HR], 0.93; 95% confidence interval [CI], 0.62-1.38; P = .71) or HPV-negative (HR, 0.75; 95% CI, 0.51-1.10; P = .15) disease.

conclusionsDespite high rates of utilization, aCRT is not associated with better survival vs aRT for OPSCC with intermediate-risk features, including HPV-negative tumors.

Indexed as

Chemoradiotherapy, AdjuvantRadiotherapy, AdjuvantAgedCarcinoma, Squamous CellFemaleHumansKaplan-Meier EstimateLogistic ModelsMaleMiddle AgedOropharyngeal NeoplasmsPropensity ScoreRegistriesRisk Factorsadjuvant chemoradiotherapyhuman papillomavirusNational Cancer Databaseoropharyngeal cancersquamous cell carcinoma

Identifiers

PMID31107584
PMCPMC9030226
OpenAlexW2945758136

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.